A Phase II, Open-Label, Multi-Arm Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer

Trial Profile

A Phase II, Open-Label, Multi-Arm Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Jul 2017

At a glance

  • Drugs AZD-1775 (Primary) ; Carboplatin (Primary) ; Durvalumab (Primary) ; Tremelimumab (Primary)
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms BALTIC
  • Sponsors AstraZeneca
  • Most Recent Events

    • 03 Jul 2017 Planned End Date changed from 8 May 2020 to 22 Jan 2021.
    • 03 Jul 2017 Planned primary completion date changed from 8 May 2020 to 22 Jan 2021.
    • 06 Jun 2017 Trial Design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top